The US Food and Drug Administration (FDA) has granted approval to Pulmonx to commence an investigational device exemption (IDE) pivotal clinical study of its Zephyr Endobronchial Valve (EBV) therapy, designed to treat emphysema. The ...
Tags: FDA, Endobronchial Valve therapy, emphysema, Zephyr EBV therapy